Digital Health, Big Data, and What Pharma Learned from COVID-19

With 2020 in the rear view mirror and 2021 ahead, speakers discuss lessons learned by pharma during the pandemic and the role digital health, interoperability, and real world evidence will play in reshaping clinical trials and accelerating future drug development.

The successful development of the COVID-19 vaccine in less than a year and its ongoing distribution has created a rare transformative moment. Long linked to high drug prices, the pharmaceutical industry now has an opportunity to reintroduce itself to the marketplace as a powerful, positive force for innovation, health and patient well-being. 

Join HIMSS for this wide-ranging discussion to learn what the digital ecosystem looked like for pharma before COVID and how it may change post-pandemic to accelerate product development and enhance patient centricity.

Key discussion points:

• Lessons learned by pharma on accelerating innovation and time-to-market during the pandemic
• How pharmaceutical companies can collaborate more effectively with healthcare providers
• The role of real world evidence to demonstrate therapeutic value and efficacy
• How AI can help analyze large amounts of data and move the needle on personalized care